BIIB — BIOGEN INC.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 875045 ·
Last close
$202.19
Market Cap
$29.85B
52W High
$219.72
52W Low
$179.15
ADV30
1,378,396
Next earnings
2026-07-29
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 2,477,800,000 | 1,816,800,000 | 459,800,000 | 319,500,000 | 29,483,100,000 | 3,382,700,000 | 10,831,400,000 |
| Dec 2025 | 2,279,400,000 | 1,783,900,000 | 385,500,000 | -48,900,000 | 29,439,500,000 | 3,008,500,000 | 11,182,700,000 |
| Sep 2025 | 2,534,700,000 | 1,860,300,000 | 606,500,000 | 466,500,000 | 29,207,500,000 | 3,862,800,000 | 11,000,000,000 |
| Jun 2025 | 2,645,500,000 | 2,040,500,000 | 851,800,000 | 634,800,000 | 28,330,200,000 | 2,758,800,000 | 10,696,200,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$2,590,800,000
Investing CF
$-1,533,300,000
Financing CF
$-322,700,000
CapEx
$-274,500,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$9.32
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$20,872,200,000
Inventory
$1,949,000,000
Receivables
$1,790,400,000
ST Investments
$900,000,000
EBIT TTM
$1,898,100,000
Pretax Income TTM
$1,623,000,000
Interest Exp TTM
$275,100,000
Analysts
29
Yahoo Snapshot (yfinance, live)
Total Revenue
$9,937,399,808
EBITDA
$3,539,599,872
Free Cash Flow
$1,930,925,056
Enterprise Value
$31,898,159,104
Total Cash
$4,282,700,032
Total Debt
$6,561,900,032
Shares Out
147,637,117
Trailing EPS
$9.31
Book Value
$126.37
ROE
7.7%
ROA
6.0%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 9,890,600,000 | 2,469,000,000 | 1,292,900,000 | 29,439,500,000 | 11,182,700,000 | — | 2,204,600,000 |
| Dec 2024 | 9,675,900,000 | 2,280,400,000 | 1,632,200,000 | 28,049,300,000 | 11,333,300,000 | — | 2,875,500,000 |
| Dec 2023 | 9,835,600,000 | 1,847,700,000 | 1,161,100,000 | 26,844,800,000 | 12,045,400,000 | — | 1,547,200,000 |
| Dec 2022 | 10,173,400,000 | 2,901,900,000 | 3,046,900,000 | 24,554,100,000 | 11,165,700,000 | — | 1,384,300,000 |
TTM Snapshot
Revenues TTM
$10,283,500,000
NetIncome TTM
$1,784,300,000
OpCashFlow TTM
$0
Assets (Latest)
$28,049,300,000
Forward EPS
$16.42
Max Pain — expiry 2026-09-18
max pain strike: $195.00 · spot: $202.19 · call oi: 4,319 · put oi: 4,822
Expected Move to 2026-09-18:
±$24.20
(11.97%) —
implied range
$177.99 –
$226.39
· ATM straddle on $200.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| BNTX | BioNTech SE | $22.59B | $89.33 | — |
| RVMD | Revolution Medicines, Inc. | $40.23B | $189.23 | — |
| MRNA | Moderna, Inc. | $21.45B | $54.07 | — |
| NBIX | NEUROCRINE BIOSCIENCES INC | $17.67B | $175.77 | — |
| ARGX | ARGENX SE | $57.44B | $918.22 | — |
News headlines (Yahoo Finance, 1h cache)
Biogen Q2 Earnings: Can New Drugs Counter Falling MS Sales?
2026-07-24 14:57 · Yahoo
Will PTC Therapeutics (PTCT) Report Negative Earnings Next Week? What You Should Know
2026-07-23 14:00 · Yahoo
Analysts Estimate Biogen Inc. (BIIB) to Report a Decline in Earnings: What to Look Out for
2026-07-22 14:00 · Yahoo
3 Profitable Stocks We Steer Clear Of
2026-07-21 12:46 · Yahoo
VERAXA Biotech Shows Regulatory Progress on Cancer Therapy Platform
2026-07-20 16:15 · Yahoo
Slate Medicines Appoints Mark W. Hahn to Board of Directors
2026-07-16 16:18 · Yahoo
Synapticure Launches Groundbreaking Ataxia Care Program, Expanding Access to Specialized Neurology Nationwide
2026-07-16 11:47 · Yahoo
3 Reasons to Avoid BIIB and 1 Stock to Buy Instead
2026-07-15 15:17 · Yahoo
Biogen Shares Decline After Detailed Diranersen Alzheimer's Study Data
2026-07-15 14:51 · Yahoo
Biogen Appoints Michael J. Parini as Chief Legal Officer
2026-07-15 12:15 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.